• Home
  • Pharmacy Medical Policy Updates

Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs have been updated Nov. 1, 2021:

Effective Dec. 1, 2021:

  • Lysosomal Storage Disorders
  • Synagis
  • Neurotrophic Keratitis
  • Urea Cycle Disorders
  • Antihypertensive Medication
  • Statin
  • Bempedoic Acid
  • Endari
  • Ocaliva
  • Oxbryta
  • Vascepa
  • Eysuvis
  • Oral Anticoagulants
  • Elagolix/Relugolix (formerly Elagolix) 

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.

Institutional Providers
Professional Providers